Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Capital World Investors

Capital World Investors raised its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 255.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,449,035 shares of the company’s stock after acquiring an additional 3,917,728 shares during the quarter. Capital World Investors owned approximately 2.46% of Sana Biotechnology worth $54,490,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Victory Capital Management Inc. purchased a new stake in shares of Sana Biotechnology during the 4th quarter worth $54,000. Hartline Investment Corp purchased a new stake in Sana Biotechnology during the 1st quarter worth about $136,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Sana Biotechnology by 42.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,257 shares of the company’s stock worth $66,000 after acquiring an additional 4,815 shares in the last quarter. Simplex Trading LLC increased its holdings in shares of Sana Biotechnology by 31.3% in the 4th quarter. Simplex Trading LLC now owns 18,080 shares of the company’s stock valued at $73,000 after acquiring an additional 4,313 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Sana Biotechnology by 351.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,800 shares of the company’s stock worth $93,000 after acquiring an additional 17,753 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Stock Up 5.8 %

SANA opened at $6.40 on Friday. Sana Biotechnology, Inc. has a 52 week low of $2.74 and a 52 week high of $12.00. The business’s 50 day moving average is $6.44 and its two-hundred day moving average is $7.58.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Sell-side analysts forecast that Sana Biotechnology, Inc. will post -1.15 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on SANA shares. Rodman & Renshaw initiated coverage on shares of Sana Biotechnology in a research note on Wednesday, June 26th. They issued a “buy” rating and a $16.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Sana Biotechnology in a research report on Thursday, May 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Sana Biotechnology presently has an average rating of “Moderate Buy” and a consensus target price of $12.75.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.